John Bartels, senior software architect, has worked in senior engineering positions at Nomos Corp., Westinghouse Electric Corp., and Digital Equipment Corp.
Timothy R. Billiar, MD , Advisory board member, consultant and co-founder, is the George Vance Foster Professor and Chair of the Department of Surgery at the University of Pittsburgh. Tim received his M.D. degree from the University of Chicago, Pritzker School of Medicine in 1983, and then completed surgical training at the University of Minnesota and the University of Pittsburgh. This included a research fellowship under the guidance of Dr. Richard L. Simmons. Dr. Billiar is a trauma surgeon and critical care physician with a longstanding interest in inflammation and organ dysfunction. His laboratory was the first to clone the human inducible nitric oxide synthase and characterize its expression and function in a number of inflammatory settings. His laboratory also investigates hepatic responses in sepsis, hemorrhagic shock and ischemia reperfusion as well as aspects of acute vascular injury. He is currently funded by two program project grants, two RO1s, and is co-director of a trauma training grant. He is a past president of the Society of University Surgeons, current president-elect of the International Nitric Oxide Society, and a current member of the Surgery, Anesthesia, Trauma NIH Study Section. In addition, he sits on the Scientific Advisory Board of four companies, has published over 300 manuscripts, and edited three books.
Steven Chang, M.S., Chief Executive Officer, is a successful technology entrepreneur with more than a decade of experience in developing complex computer models, optimization algorithms, and data mining systems. He is the Chairman of the board of directors for SCAI (Society for Complexity in Acute Illnesses). As founding CEO of Futuristics Labs, Steve raised two rounds of financing totaling over $10 million. Futuristics' proprietary technologies enabled real-time ad hoc query processing on terabyte sized databases with no loss in data resolution. Prior to founding Futuristics, Steve headed up the Intelligent Software Systems group at Westinghouse/CBS Corporation's Science and Technology Center and developed decision optimization and computer modeling systems that were successfully deployed in many Fortune 500 companies, including Kraft Foods, Colgate-Palmolive, Nestle, and Airborne Express. He was also instrumental in establishing the first Westinghouse presence on the Internet and was the recipient of two George Westinghouse Signature Awards for Excellence. Steve attained both BS and MS degrees in Electrical Engineering from the Rensselaer Polytechnic Institute.
Gilles Clermont, MD, Advisory board member and co-founder, is another inventor of the Immunetrics technology. He serves as both an attending physician at the University of Pittsburgh Medical Center and as an Assistant Professor in Critical Care Medicine at the University of Pittsburgh. He earned his medical degree from McGill University, and completed his residency training in Montreal. Gilles participates in cost-effectiveness and outcomes research in critical care, transplantation, and cardiopulmonary resuscitation. As a physician with special expertise in modeling, computer programming, and data analysis, he has an active interest in looking at improved measures of performance in the delivery of critical care services.
Mitchell P. Fink, MD, Advisory board member, consultant and co-founder, is Professor and Chairman, Department of Critical Care Medicine and the Watson Professor of Surgery at the University of Pittsburgh Medical School. Mitch received his medical degree from Washington University School of Medicine. He then completed his internship and residency in surgery at the National Naval Center, Bethesda, Maryland. An author of more than 150 peer-reviewed publications, more than 60 book chapters and review articles, and 13 books (two of which are "in press"), Mitch is particularly interested in alterations in the function of the intestinal barrier in sepsis and shock. He is on the Editorial Boards of several scientific journals, including the American Journal of Physiology Gastrointestinal and Liver Physiology, Critical Care Medicine, Intensive Care Medicine, and Shock. Mitch's research program has been continuously funded by the National Institutes of Health for more than 17 years. He is a member of the Society of Critical Care Medicine, the American Surgical Association, and the James IV Association of Surgeons, among other professional organizations. Mitch is also on the Defense Sciences Research Council (DSRC) of the Defense Advanced Research Projects Agency (DARPA) and the Surgery, Anesthesiology and Trauma (SAT) study section of the NIH. He received the Millennium Lecturer award from the Society of Critical Care Medicine in 2000, and has received numerous other awards and honors. He is an inventor or co-inventor on several issued or pending U.S. patents, and recently founded Critical Therapeutics, Inc., a venture capital-funded biotechnology company based in Cambridge, Massachusetts. Mitch presently serves on the scientific advisory boards of numerous biotechnology companies, including Medinox, Inc., Somatogen, Inc., and Inotek, Inc. He has also served as consultant to numerous biotechnology and pharmaceutical companies, including Chiron, GlaxoSmithKline, and Eli Lilly.
Liangsheng Qian, software engineer, is a computer science graduate of Carnegie Mellon University.
Yoram Vodovotz, Ph.D., Advisory board member, consultant and co-founder, rounds out the team of Immunetrics inventors. Yoram received his Ph.D. in immunology at Cornell University Weill Graduate School of Medical Sciences, carried out two postdoctoral fellowships at the National Cancer Institute, and was subsequently the Director of Cellular and Molecular Research at the nonprofit Cardiovascular Research Institute at Washington Hospital Center. Currently, Yoram is Associate Professor of Surgery at the University of Pittsburgh, where he is continuing his research interests on nitric oxide and inflammation in sepsis, hemorrhagic shock, cancer, and vascular biology.
John Bartels, senior software architect, has worked in senior engineering positions at Nomos Corp., Westinghouse Electric Corp., and Digital Equipment Corp.
Timothy R. Billiar, MD , Advisory board member, consultant and co-founder, is the George Vance Foster Professor and Chair of the Department of Surgery at the University of Pittsburgh. Tim received his M.D. degree from the University of Chicago, Pritzker School of Medicine in 1983, and then completed surgical training at the University of Minnesota and the University of Pittsburgh. This included a research fellowship under the guidance of Dr. Richard L. Simmons. Dr. Billiar is a trauma surgeon and critical care physician with a longstanding interest in inflammation and organ dysfunction. His laboratory was the first to clone the human inducible nitric oxide synthase and characterize its expression and function in a number of inflammatory settings. His laboratory also investigates hepatic responses in sepsis, hemorrhagic shock and ischemia reperfusion as well as aspects of acute vascular injury. He is currently funded by two program project grants, two RO1s, and is co-director of a trauma training grant. He is a past president of the Society of University Surgeons, current president-elect of the International Nitric Oxide Society, and a current member of the Surgery, Anesthesia, Trauma NIH Study Section. In addition, he sits on the Scientific Advisory Board of four companies, has published over 300 manuscripts, and edited three books.
Steven Chang, M.S., Chief Executive Officer, is a successful technology entrepreneur with more than a decade of experience in developing complex computer models, optimization algorithms, and data mining systems. He is the Chairman of the board of directors for SCAI (Society for Complexity in Acute Illnesses). As founding CEO of Futuristics Labs, Steve raised two rounds of financing totaling over $10 million. Futuristics' proprietary technologies enabled real-time ad hoc query processing on terabyte sized databases with no loss in data resolution. Prior to founding Futuristics, Steve headed up the Intelligent Software Systems group at Westinghouse/CBS Corporation's Science and Technology Center and developed decision optimization and computer modeling systems that were successfully deployed in many Fortune 500 companies, including Kraft Foods, Colgate-Palmolive, Nestle, and Airborne Express. He was also instrumental in establishing the first Westinghouse presence on the Internet and was the recipient of two George Westinghouse Signature Awards for Excellence. Steve attained both BS and MS degrees in Electrical Engineering from the Rensselaer Polytechnic Institute.
Gilles Clermont, MD, Advisory board member and co-founder, is another inventor of the Immunetrics technology. He serves as both an attending physician at the University of Pittsburgh Medical Center and as an Assistant Professor in Critical Care Medicine at the University of Pittsburgh. He earned his medical degree from McGill University, and completed his residency training in Montreal. Gilles participates in cost-effectiveness and outcomes research in critical care, transplantation, and cardiopulmonary resuscitation. As a physician with special expertise in modeling, computer programming, and data analysis, he has an active interest in looking at improved measures of performance in the delivery of critical care services.
Mitchell P. Fink, MD, Advisory board member, consultant and co-founder, is Professor and Chairman, Department of Critical Care Medicine and the Watson Professor of Surgery at the University of Pittsburgh Medical School. Mitch received his medical degree from Washington University School of Medicine. He then completed his internship and residency in surgery at the National Naval Center, Bethesda, Maryland. An author of more than 150 peer-reviewed publications, more than 60 book chapters and review articles, and 13 books (two of which are "in press"), Mitch is particularly interested in alterations in the function of the intestinal barrier in sepsis and shock. He is on the Editorial Boards of several scientific journals, including the American Journal of Physiology Gastrointestinal and Liver Physiology, Critical Care Medicine, Intensive Care Medicine, and Shock. Mitch's research program has been continuously funded by the National Institutes of Health for more than 17 years. He is a member of the Society of Critical Care Medicine, the American Surgical Association, and the James IV Association of Surgeons, among other professional organizations. Mitch is also on the Defense Sciences Research Council (DSRC) of the Defense Advanced Research Projects Agency (DARPA) and the Surgery, Anesthesiology and Trauma (SAT) study section of the NIH. He received the Millennium Lecturer award from the Society of Critical Care Medicine in 2000, and has received numerous other awards and honors. He is an inventor or co-inventor on several issued or pending U.S. patents, and recently founded Critical Therapeutics, Inc., a venture capital-funded biotechnology company based in Cambridge, Massachusetts. Mitch presently serves on the scientific advisory boards of numerous biotechnology companies, including Medinox, Inc., Somatogen, Inc., and Inotek, Inc. He has also served as consultant to numerous biotechnology and pharmaceutical companies, including Chiron, GlaxoSmithKline, and Eli Lilly.
Liangsheng Qian, software engineer, is a computer science graduate of Carnegie Mellon University.
Yoram Vodovotz, Ph.D., Advisory board member, consultant and co-founder, rounds out the team of Immunetrics inventors. Yoram received his Ph.D. in immunology at Cornell University Weill Graduate School of Medical Sciences, carried out two postdoctoral fellowships at the National Cancer Institute, and was subsequently the Director of Cellular and Molecular Research at the nonprofit Cardiovascular Research Institute at Washington Hospital Center. Currently, Yoram is Associate Professor of Surgery at the University of Pittsburgh, where he is continuing his research interests on nitric oxide and inflammation in sepsis, hemorrhagic shock, cancer, and vascular biology.